{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2008"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2061270"],"location":["Greece"],"study_start_month":["11"],"keyword":["Second line","Irinotecan","Capecitabine (Xeloda)","Oxaliplatin","Capecitabine","Cetuximab (Erbitux)","Cetuximab","Metastatic colorectal cancer"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC","description":"This phase II study will evaluate which is the best way to administer cetuximab after recurrence in 1st line irinotecan+bevacizumab based treatment and to obtain results of the efficacy of the oxaliplatin+cetuximab combination as 2nd line treatment.","dates":{"creation":"2008-11-15"},"accession":"2061270","cross_references":{"ClinicalTrials___gov":["NCT00755534"]}}